Management of rhinosinusitis today

Clinical Pulmonary Medicine

Volumn 15, Issue 6, 2008, Pages 332-341

  Alobid, Isam ^a   Mullol, Joaquim ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b Hospital Municipal de Badalona   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Chronic rhinosinusitis; Medical treatment; Nasal polyposis; Surgical treatment

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; AMOXICILLIN; AMPHOTERICIN B; ANTIHISTAMINIC AGENT; BACTERIUM LYSATE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BROMHEXINE; BUDESONIDE; CEFUROXIME; CETIRIZINE; CIPROFLOXACIN; CLAVULANIC ACID; DECONGESTIVE AGENT; DEXAMETHASONE; ERYTHROMYCIN; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; MONTELUKAST; NAPHAZOLINE; NEOMYCIN; PLACEBO; PREDNISOLONE; PROTON PUMP INHIBITOR; ROXITHROMYCIN; TIXOCORTOL PIVALATE; TRAMAZOLINE;

CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DESENSITIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC SURGERY; ENDOSCOPY; HUMAN; INFLAMMATORY DISEASE; LAVAGE; NOSE CONGESTION; NOSE OBSTRUCTION; NOSE POLYP; NOSE SURGERY; PEAK NASAL INSPIRATORY FLOW; QUALITY OF LIFE; REVIEW; RHINOMETRY; RHINORRHEA; RHINOSINUSITIS; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 67650381987     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e31818d0df3     Document Type: Review

References (109)

1. Melen I. Chronic sinusitis: clinical and pathophysiological aspects. Acta Otolaryngol. 1994;515:45-48.
2. Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: bench to bedside-current findings, future directions. J Allergy Clin Immunol. 1997;99:S829-S848.
3. 3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology. 2007;45:97-101.
4. Fokkens W, Lund V, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology. 2007;(suppl 20):1-136.
5. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirininduced asthma. AIANE Investigators. European network on aspirininduced asthma. Eur Respir J. 2000;16:432-436.
6. Guilemany JM, Alobid I, Angrill J, et al. The impact of bronchiectasis associated to sinonasal disease on quality of life. Respir Med. 2006; 100:1997-2003.
7. Hens G, Vanaudenaerde BM, Bullens DM, et al. Sinonasal pathology in nonallergic asthma and COPD: 'united airway disease' beyond the scope of allergy. Allergy. 2008;63:261-267.
8. Hurst JR, Wilkinson TM, Donaldson GC, et al. Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med. 2004;98:767-770.
9. Hens G, Hellings PW. The nose: gatekeeper and trigger of bronchial disease. Rhinology. 2006;44:179-187.
10. Johansson A, Bende M, Millqvist E, et al. Nasobronchial relationship after cold air provocation. Respir Med. 2000;94:1119-1122.
11. Barnes KC. Genetic epidemiology of health disparities in allergy and clinical immunology. J Allergy Clin Immunol. 2006;117:243-254.
12. Schmid M, Gode U, Schafer D, et al. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Acta Otolaryngol. 1999;119:277-280.
13. Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1999;160:291-296.
14. Braunstahl GJ, Hellings PW. Nasobronchial interaction mechanisms in allergic airways disease. Curr Opin Otolaryngol Head Neck Surg. 2006;14:176-182.
15. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope. 2003;113:1199-1205.
16. Greisner WA III, Settipane GA. Hereditary factor for nasal polyps. Allergy Asthma Proc. 1996;17:283-286.
17. Rugina M, Serrano E, Klossek JM, et al. Epidemiological and clinical aspects of nasal polyposis in France; the ORLI group experience. Rhinology. 2002;40:75-79.
18. Klossek JM, Neukirch F, Pribil C, et al. Prevalence of nasal polyposis in France: a crosssectional, case-control study. Allergy. 2005;60:233-237.
19. Kim J, Hanley JA. The role of woodstoves in the etiology of nasal polyposis. Arch Otolaryngol Head Neck Surg. 2002;128:682-686.
20. Alobid I, Benítez P, Bernal-Sprekelsen M, et al. The impact of asthma and aspirin sensitivity on quality of life of patients with nasal polyposis. Qual Life Res. 2005;14:789-793.
21. Alobid I, Benitez P, Bernal-Sprekelsen M, et al. Nasal polyposis and its impact on quality of life. Comparison between the effects of medical and surgical treatments. Allergy. 2005;125:215-219.
22. Gliklich RE, Metson R. Techniques for outcomes research in chronic sinusitis. Laryngoscope. 1995;105:387-390.
23. Xaubet A, Mullol J, Lopez E, et al. Comparison of the role of nasal polyp and normal nasal mucosal epithelial cells on in vitro eosinophil survival. Mediation by GM-CSF and inhibition by dexamethasone. Clin Exp Allergy. 1994;24:307-317.
24. Mullol J, Xaubet A, Lopez E, et al. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax. 1995;50:270-274.
25. Mullol J, Lopez E, Roca-Ferrer J, et al. Effects of topical anti- inflammatory drugs on eosinophil survival primed by epithelial cells. Additive effect of glucocorticoids and nedocromil sodium. Clin Exp Allergy. 1997;27:1432-1441.
26. Mullol J, Roca-Ferrer J, Xaubet A, et al. Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells. Respir Med. 2000;94:428-431.
27. Xaubet A, Mullol J, Roca-Ferrer J, et al. Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells. Respir Med. 2001;95:408-414.
28. Parikh A, Scadding GK, Darby Y, et al. Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray. Rhinology. 2001;39:75-79.
29. Lavigne F, Cameron L, Renzi PM, et al. Intrasinus administration of topical budesonide to allergic patients with chronic rhinosinusitis following surgery. Laryngoscope. 2002;112:858-864.
30. Cuenant G, Stipon JP, Plante-Longchamp G, et al. Efficacy of endonasal neomycin-tixocortol pivalate irrigation in the treatment of chronic allergic and bacterial sinusitis. ORL J Otorhinolaryngol Relat Spec. 1986;48:226-232.
31. Sykes DA, Wilson R, Chan KL, et al. Relative importance of antibiotic and improved clearance in topical treatment of chronic mucopurulent rhinosinusitis. A controlled study. Lancet. 1986;2:359-360.
32. Lund VJ, Black JH, Szabo LZ, et al. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. Rhinology. 2004;42:57-62.
33. McNally PA, White MV, Kaliner MA. Sinusitis in an allergist's office: analysis of 200 consecutive cases. Allergy Asthma Proc. 1997;18:169-175.
34. Subramanian HN, Schechtman KB, Hamilos DL. A retrospective analysis of treatment outcomes and time to relapse after intensive medical treatment for chronic sinusitis. Am JRhinol. 2002;16:303-312.
35. Legent F, Bordure P, Beauvillain C, et al. A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy. 1994;40:8-15.
36. Namyslowski G, Misiolek M, Czecior E, et al. Comparison of the efficacy and tolerability of amoxycillin/clavulanic acid 875 mg b. i.d. with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults. J Chemother. 2002;14:508-517.
37. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl. 1996;525:73-78.
38. Gandhi A, Brodsky L, Ballow M. Benefits of antibiotic prophylaxis in children with chronic sinusitis: assessment of outcome predictors. Allergy Proc. 1993;14:37-43.
39. Suzuki H, Shimomura A, Ikeda K, et al. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope. 1997;107:1661-1666.
40. Miyanohara T, Ushikai M, Matsune S, et al. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope. 2000;110:126-131.
41. Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. 2001;121:83-892.
42. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomized, controlled trial. Laryngoscope. 2004;114:923-930.
43. Wallwork B, Coman W, Mackay-Sim A, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116:189-193.
44. Otten FW. Conservative treatment of chronic maxillary sinusitis in children. Long-term follow-up. Acta Otorhinolaryngol Belg. 1997;51: 173-175.
45. Van Bever HP, Bosmans J, Stevens WJ. Nebulization treatment with saline compared to bromhexine in treating chronic sinusitis in asthmatic children. Allergy. 1987;42:33-36.
46. Szmeja Z, Golusinski W, Mielcarek-Kuchta D, et al. Use of mucolytic preparations (Mucosolvan) in selected diseases of the upper respiratory tract. Part II. Otolaryngol Pol. 1997;51:480-6 [article in Polish].
47. Bhattacharyya Nl. The economic burden and symptom manifestations of chronic rhinosinusitis. Am J Rhinol. 2003;17:27-32.
48. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc. 1999;74:877-884.
49. Ponikau JU, Sherris DA, Kita H, et al. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2002;110:862-866.
50. Ponikau JU, Sherris DA, Weaver A, et al. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebocontrolled, double-blind pilot trial. J Allergy Clin Immunol. 2005;115: 125-131.
51. Weschta M, Rimek D, Formanek M, et al. Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol. 2004;113:1122-1128.
52. Ebbens FA, Scadding GK, Badia L, et al. Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2006;118:1149-1156.
53. Kennedy DW, Kuhn FA, Hamilos DL, et al. Treatment of chronic rhinosinusitis with high dose oral terbinafine: A double blind, placebo-controlled study. Laryngoscope. 2005;115:1793-9.
54. Heintz B, Schlenter WW, Kirsten R, et al. Clinical efficacy of BronchoVaxom in adult patients with chronic purulent sinusitis-a multi-centric, placebo-controlled, double-blind study. Int J Clin Pharmacol Ther Toxicol. 1989;27:530-534.
55. Bachmann G, Hommel G, Michel O. Effect of irrigation of the nose with isotonic salt solution on adult patients with chronic paranasal sinus disease. Eur Arch Otorhinolaryngol. 2000;257:537-541.
56. Taccariello M, Parikh A, Darby Y, et al. Nasal douching as a valuable adjunct in the management of chronic rhinosinusitis. Rhinology. 1999; 37:29-32.
57. Rabago D, Zgierska A, Mundt M, et al. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomized controlled trial. J Fam Pract. 2002;51:1049-1055.
58. Shoseyov D, Bibi H, Shai P, et al. Treatment with hypertonic saline versus normal saline nasal wash of pediatric chronic sinusitis. J Allergy Clin Immunol. 1998;101:602-605.
59. Friedman M, Vidyasagar R, Joseph N. A randomized, prospective, double-blind study on the efficacy of Dead Sea salt nasal irrigations. Laryngoscope. 2006;116:878-882.
60. Pinto JM, Elwany S, Baroody FM, et al. Effects of saline sprays on symptoms after endoscopic sinus surgery. Am J Rhinology. 2006;20: 191-196.
61. Pang YT, Willatt DJ. Do antral washouts have a place in the current management of chronic sinusitis? J Laryngol Otol. 1996;110:926-928.
62. Weaver EM. Association between gastroesophageal reflux and sinusitis, otitis media, and laryngeal malignancy: a systematic review of the evidence. Am J Med. 2003;115:81-89.
63. Blanc PD, Trupin L, Earnest G, et al. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest. 2001;120:1461-1467.
64. Hopkins C, Browne JP, Slack R, et al. Complications of surgery for nasal polyposis and chronic rhinosinusitis: the results of a national audit in England and Wales. Laryngoscope. 2006;116:1494-1499.
65. Deal RT, Kountakis SE. Significance of nasal polyps in chronic rhinosinusitis: symptoms and surgical outcomes. Laryngoscope. 2004; 114:1932-1935.
66. Giger R, Dulguerov P, Quinodoz D, et al. Chronic panrhinosinusitis without nasal polyps: long-term outcome after functional endoscopic sinus surgery. Otolaryngol Head Neck Surg. 2004;131:534-541.
67. Senior BA, Kennedy DW, Tanabodee J, et al. Long-term impact of functional endoscopic sinus surgery on asthma. Otolaryngol Head Neck Surg. 1999;121:66-68.
68. Dejima K, Hama T, Miyazaki M, et al. A clinical study of endoscopic sinus surgery for sinusitis in patients with bronchial asthma. Int Arch Allergy Immunol. 2005;138:97-104.
69. Dhong HJ, Jung YS, Chung SK, et al. Effect of endoscopic sinus surgery on asthmatic patients with chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2001;124:99-104.
70. Dinis PB, Gomes A. Sinusitis and asthma: how do they interrelate in sinus surgery? Am J Rhinol. 1997;11:421-428.
71. Amar YG, Frenkiel S, Sobol SE. Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter's triad. J Otolaryngol. 2000;29:7-12.
72. Mehanna H, Mills J, Kelly B, et al. Benefit from endoscopic sinus surgery. Clin Otolaryngol. 2002;27:464-471.
73. Kountakis SE, Bradley DT. Effect of asthma on sinus computed tomography grade and symptom scores in patients undergoing revision functional endoscopic sinus surgery. Am J Rhinol. 2003;17:215-219.
74. Mygind N, Pedersen CB, Prytz S, et al. Treatment of nasal polyps with intranasal beclomethasone dipropionate aerosol. Clin Allergy. 1975;5: 159-164.
75. Deuschl H, Drettner B. Nasal polyps treated by beclomethasone nasal aerosol. Rhinology. 1977;15:17-23.
76. Holopainen E, Grahne B, Malmberg H, et al. Budesonide in the treatment of nasal polyposis. Eur J Respir Dis Suppl. 1982;122:221-228.
77. Tos M, Svendstrup F, Arndal H, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol. 1998;12:183-189.
78. Vendelo Johansen L, Illum P, Kristensen S, et al. The effect of budesonide (Rhinocort) in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol. 1993;18:524-527.
79. Lildholdt T, Rundcrantz H, Lindqvist N. Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol. 1995;20:26-30.
80. Holmberg K, Juliusson S, Balder B, et al. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol. 1997;78:270-276.
81. Keith P, Nieminen J, Hollingworth K, et al. Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy. 2000;30:1460-1468.
82. Penttila M, Poulsen P, Hollingworth K, et al. Doserelated efficacy and tolerability of fluticasone propionate nasaldrops 400 microg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebocontrolled randomized study in adult patients. Clin Exp Allergy. 2000; 30:94-102.
83. Lund VJ, Flood J, Sykes AP, et al. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg. 1998;124:513-518.
84. Aukema AA, Mulder PG, Fokkens WJ. Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. J Allergy Clin Immunol. 2005;115: 1017-1023.
85. Small CB, Hernandez J, Reyes A, et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol. 2005;116:1275-1281.
86. Stjarne P, Mosges R, Jorissen M, et al. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch Otolaryngol Head Neck Surg. 2006;132:179-185.
87. Stjarne P, Blomgren K, Cayé-Thomasen P, et al. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebocontrolled study. Acta Otolaryngol. 2006;126:606-612.
88. Lildholdt T, Fogstrup J, Gammelgaard N, et al. Surgical versus medical treatment of nasal polyps. Acta Otolaryngol. 1988;105:140-143.
89. van Camp C, Clement PA. Results of oral steroid treatment in nasal polyposis. Rhinology. 1994;32:5-9.
90. Damm M, Jungehulsing M, Eckel HE, et al. Effects of systemic steroid treatment in chronic polypoid rhinosinusitis evaluated with magnetic resonance imaging. Otolaryngol Head Neck Surg. 1999;120:517-523.
91. Benitez P, Alobid I, De Haro J, et al. A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. Laryngoscope. 2006;116:770-775.
92. Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clinical Immunol. 2006;118:128-133.
93. Becker SS, Rasamny JK, Han JK, et al. Steroid injection for sinonasal polyps: the University of Virginia experience. Am J Rhinol. 2007;21: 64-69.
94. Elbez M, De Pressigny M, Halimi P, et al. Does the use of nasal vasoconstrictor agents change tomodensitometric images of nasosi- nusal polyposis? Ann Otolaryngol Chir Cervicofac. 1993;110:277-280 [article in French].
95. Johansson L, Oberg D, Melen I, et al. Do topical nasal decongestants affect polyps? Acta Otolaryngol. 2006;126:288-290.
96. Haye R, Aanesen JP, Burtin B, et al. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol. 1998;112: 1042-1046.
97. Ricchetti A, Landis BN, Maffioli A, et al. Effect of anti-fungal nasal lavage with amphotericin B on nasal polyposis. J Laryngol Otol. 2002;116:261-263.
98. Corradini C, Del Ninno M, Buonomo A, et al. Amphotericin B and lysine acetylsalicylate in the combined treatment of nasal polyposis associated with mycotic infection. J Investig Allergol Clin Immunol. 2006;16:188-193.
99. Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79:18-20.
100. Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J. 1999;78:604-606.
101. Ragab S, Parikh A, Darby YC, et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31:1385-1391.
102. Mostafa BE, Abdel HH, Mohammed HE, et al. Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2005;67:148.
103. Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol. 2003;24:159-168.
104. Nucera E, Schiavino D, Milani A, et al. Effects of lysine- acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies. Thorax. 2000;55:75-78.
105. Scadding GK, Hassab M, Darby YC, et al. Intranasal lysine aspirin in recurrent nasal polyposis. Clin Otolaryngol. 1995;20:561-563.
106. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope. 2005;115:1385-1390.
107. Ogata N, Darby Y, Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007;121:1156-1160.
108. Dalziel K, Stein K, Round A, et al. Systematic review of endoscopic sinus surgery for nasal polyps. Health Technol Assess. 2003;7:1-159.
109. Batra PS, Kern RC, Tripathi A, et al. Outcome analysis of endoscopic sinus surgery in patients with nasal polyps and asthma. Laryngoscope. 2003;113:1703-1706.